Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-REG BP: Empagliflozin in Hypertensive T2D Patients
NCT01370005Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: HbA1c Change From Baseline at 12 weeks and Mean 24-hour Systolic Blood Pressure Change From Baseline at 12 weeks. Started Jun 2011; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT01370005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370005.